Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems Inc (KRMD) specializes in innovative subcutaneous infusion systems for critical therapies. This hub provides authorized updates about the company's medical device developments, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely announcements including product launch details, financial disclosures, and manufacturing updates. Our curated collection ensures access to verified information about FREEDOM infusion systems and related technologies.
Key updates cover FDA clearances, partnership announcements, clinical application insights, and operational developments. All content maintains strict compliance with financial disclosure regulations and medical device reporting standards.
Bookmark this page for streamlined access to KRMD's latest advancements in immunoglobulin therapy delivery systems. Check regularly for official updates directly impacting the medical device sector and chronic care treatment landscapes.
KORU Medical Systems (NASDAQ: KRMD) reported strong Q2 2022 results, showcasing an 18.4% increase in net sales to $6.5 million, driven by substantial growth in novel therapies and domestic core business despite supply chain challenges. The revenue guidance for 2022 has been raised to $27.0 to $27.5 million, reflecting optimism for continued growth. However, gross profit percentage fell to 51.1% due to accelerated amortization and manufacturing variances. The company also reported a net loss of $2.9 million, with expenses rising to $7.0 million due to strategic investments.
KORU Medical Systems (NASDAQ: KRMD) will report its second quarter 2022 financial results on August 3, 2022, at 4:30 p.m. ET.
Management will host a conference call to discuss these results and provide an update. U.S. participants can access the call by dialing (877)-407-0784, while international callers should dial (201)-689-8560. The event will also be available via a live and archived webcast on the company's website.
KORU Medical Systems (NASDAQ: KRMD) reported a strong first quarter of 2022, achieving a 15% year-over-year net sales growth to $6.2 million. This marks the second consecutive quarter of double-digit growth, driven by domestic core sales increasing by 13.2% to $5 million. The company received its fourth FDA clearance in five months and expanded its pipeline for novel therapies. However, operating expenses rose to $6.7 million, leading to a net loss of $2.5 million or $(0.06) per diluted share. KORU reaffirms guidance for full-year revenues of $26.5 to $27.0 million.
KORU Medical Systems (NASDAQ: KRMD) has received 510k clearance for its FreedomEdge infusion system, which will now deliver pegcetacoplan (EMPAVELI®/Aspaveli®) in the U.S. This drug treats paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder affecting about 15,000 patients globally. The company's President emphasized the expansion of their infusion technology to enhance patient care and emphasized their online training support for healthcare providers. This development aligns with KORU's strategy to broaden its infusion solutions.
KORU Medical Systems (NASDAQ: KRMD) will release its first quarter 2022 financial results on May 4, 2022, at 4:30 p.m. ET. Management will host a conference call to discuss these results and provide a corporate update. Interested parties can join the call by dialing (877)-407-0784 for U.S. participants or (201)-689-8560 for international callers, using conference ID: 13728821. A live and archived webcast will also be available on the company's website.
KORU Medical Systems (NASDAQ: KRMD) has appointed Brian Case as its new Chief Technology Officer. With over 20 years in R&D, including roles at Fresenius Kabi and Cook Medical, Case will lead product development and innovation. He aims to enhance KORU's technology strategy to support a global drug delivery portfolio. CEO Linda Tharby expressed confidence in Case's ability to drive value through his extensive experience. This leadership change comes at a vital time for KORU, as it seeks to innovate in home infusion solutions.
KORU Medical Systems (NASDAQ: KRMD) reported a 60% increase in fourth-quarter net revenues, reaching $6.5 million, driven by growth in all business areas. For the full year, revenues were $23.5 million, a 2.8% decline from last year due to reduced novel therapies revenue. The company achieved three new 510(k) clearances and announced a five-year strategic plan aiming for $60 million in revenues by 2026. Despite a net loss of $4.6 million in 2021, cash reserves stand at $25.3 million as they prepare for 2022 revenue growth projected at $26.0 to $27.0 million.
KORU Medical Systems (NASDAQ: KRMD) will report its fourth quarter and full year 2021 financial results on March 2, 2021. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can access the call by dialing the designated numbers, with an archived webcast available for six months on their website. The company specializes in innovative home infusion solutions aimed at improving patients' quality of life.
KORU Medical Systems (NASDAQ: KRMD) has received FDA 510(k) clearance to expand the on-label use of its FREEDOM60 Infusion System. The new clearance includes two additional subcutaneous Ig medications: Cutaquig® from Octapharma and Xembify® from Grifols. This move enhances KORU Medical's position in the home infusion market, providing patients and providers with more options for immunoglobulin therapy. The FREEDOM60 is now cleared for use with more SCIg drugs than any other system, reaffirming the company's leadership in this growing market.
FAQ
What is the current stock price of Koru Med Sys (KRMD)?
What is the market cap of Koru Med Sys (KRMD)?
